A multi-center, non-randomized, open-label safety study of BLP25 liposome vaccine (L-BLP25) [cancer vaccine BLP25; Stimuvax] in non-small cell lung cancer (NSCLC) patients with unresectable stage III disease
Phase of Trial: Phase I/II
Latest Information Update: 06 Dec 2018
At a glance
- Drugs Tecemotide (Primary) ; Cyclophosphamide
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Merck KGaA
- 08 Aug 2012 Actual end date (1 Sep 2009) added as reported by ClinicalTrials.gov.
- 02 Jun 2008 Two-year survival data presented at ASCO 2008.
- 28 May 2008 The expected completion date for this trial is now 1 Jun 2008, according to ClinicalTrials.gov.